Aqara To Unveil New Smart Home Devices at IFA 2023, Embracing the Future of Connected Living
31.8.2023 10:00:00 EEST | Business Wire | Press release
Aqara, a leading provider of smart home products, is thrilled to announce its attendance at this year’s IFA show, where it will unveil multiple new smart home devices. These include the Smart Lock U200, the Camera E1, the Dual Relay Module T2, the Ceiling Light T1M, and an EU-style wall outlet. Aqara will be showcasing these new devices along with other smart home technology and solutions at its booth (H22, 214).
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20230831580646/en/
Aqara unveils new smart home devices at IFA 2023 (Photo: Business Wire)
With a commitment to making smart home technology more accessible to households worldwide, Aqara continues to expand its product portfolio to enable various home automation use cases. The five new products previewed at IFA are expected to become available for order in the coming months.
Smart Lock U200 - As a retrofit solution, Aqara’s new Smart Lock U200 offers the convenience of keyless home access to a broad user base. The lock operates with existing cylinders and requires no drilling or door modifications. As Aqara’s first Matter-over-Thread smart lock, the U200 will be interoperable with a wide array of smart home ecosystems and products. Using an Aqara NFC card or specified NFC-enabled mobile devices, users can unlock easier than ever before. Other secure access options include auto-unlock, fingerprints, PIN codes and mobile apps. Aqara also plans to initiate its first crowdfunding campaign on Kickstarter for the Smart Lock U200 later this year.
Camera E1 - Aqara is expanding its home surveillance camera portfolio with the 2K, Pan/Tilt Camera E1. Similar to other indoor home cameras from the Company, this new camera supports major third-party platforms like Apple Home (including HomeKit Secure Video), Amazon Alexa, and Google Home. Built upon Wi-Fi 6 and Bluetooth 5.2, the camera enables smoother live view and easier pairing experience. Other features of the E1 camera include AI-enabled person detection, person tracking and flexible storage options such as cloud storage, microSD card, and NAS storage.
Dual Relay Module T2 - The Dual Relay Module T2 is a versatile solution for home automation, allowing easy control of various devices ranging from lights, motorized window coverings, garage doors, boilers, to electric heaters and underfloor heating. Built upon Zigbee 3.0, the dual relay module features Matter-over-bridge support and is compatible with major third-party platforms. It also allows users to monitor energy consumption and ensures peace of mind with safety features like overheat protection, overload protection, and configurable power limits. Powered by AC (100-250V) or DC (24-60V), the 2-channel relay supports a total (and per-channel) loads of up to 10 Amps.
Ceiling Light T1M - Following the LED Strip T1, which was announced in August 2023, Aqara is introducing its second smart lighting device to the global market. With an approximate diameter of 50 centimeters, the Ceiling Light T1M offers a broad spectrum of hues from dimmable whites to 16 million vibrant colors, allowing users to set the atmospheric lighting for different occasions and moods. Additional features include an independently addressable RGB ring for gradient effects and integration into home automation, such as using the RGB ring as a status light to indicate potential threats like an open door or water leak. Similar to other Zigbee devices from Aqara, the Ceiling Light T1M features the low idle consumption, Matter-over-bridge support, and the wide compatibility with major platforms.
EU-style wall outlet - Finally, Aqara is introducing a smart wall socket for the EU market. This outlet allows easy control of plugged devices via mobile apps, voice assistants and home automation. It also helps users track energy consumption. Moreover, this new outlet can be configured to sense and report the status of the plugged device, making it possible to use the on/off status of an appliance as an automation trigger. For example, to close the curtains and dim the lights when the TV is turned on, or to notify the user when the washing machine finished the laundry. As a repeater of the Zigbee network, this socket outlet also enhances network reliability and responsiveness of other compatible smart home devices.
“Aqara is at the forefront of innovating the smart home experience, and these new products are a testament to our dedication. Each of them is crafted with the user's convenience and lifestyle in mind, reflecting our commitment to quality and innovation,” said Cathy You, Aqara Senior Vice President, Global Business and Strategy. “We invite everyone to join us at our booth to experience firsthand the future we're building together.”
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20230831580646/en/
Contact information
For Media Inquiries:
media@aqara.com
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Pelago Bioscience Acquires RG Discovery, Forming an Integrated Drug Discovery Partner Spanning Biology and Chemistry15.6.2026 10:00:00 EEST | Press release
Pelago Bioscience, a specialist drug discovery focused contract research organization (CRO), known for its industry-leading cell-based target engagement assays, is pleased to announce the acquisition of RG Discovery, and thereby adding deep expertise in medicinal chemistry, custom synthesis, and integrated drug discovery. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260615340933/en/ Michael Dabrowski, Chief Executive Officer of Pelago Bioscience By combining Pelago Bioscience's biology-focused capabilities with RG Discovery's chemistry expertise, the enlarged platform will enable drug discovery teams to accelerate decision-making, streamline workflows, and advance programs more efficiently from hit identification through lead optimization. "Drug discovery increasingly requires seamless integration between chemistry and biology," said Michael Dabrowski, Chief Executive Officer of Pelago Bioscience. "By bringing RG Discovery
LTM Launches BlueVerse™ for iRun to Outcreate Managed Services in the Agentic AI Era15.6.2026 09:10:00 EEST | Press release
LTM, the Business Creativity partner to the world’s largest enterprises, today announced the launch of BlueVerse™ for iRun, an AI-native managed services model designed to transform traditional IT operations into a resilient, intelligent, and outcome-driven operating model. As enterprise environments grow more complex—spanning hybrid cloud, SaaS, and AI-driven ecosystems—traditional managed services models are increasingly constrained by siloed teams, static processes, and effort-led scaling. BlueVerse for iRun addresses this shift by moving beyond headcount-based delivery to a platform-led approach powered by agentic AI, knowledge convergence, and process-as-code. Built on the BlueVerse ecosystem, iRun creates a unified intelligence layer that brings together enterprise data, telemetry, workflows, and operational context—enabling AI to reason across systems, identify root causes, and execute actions within governed guardrails. iRun combines AI agents and human expertise to shift opera
Azafaros to Present at BIO International Convention 202615.6.2026 08:00:00 EEST | Press release
Azafaros, a private company building a portfolio to become a leader in lysosomal storage disorders (LSDs), focused on addressing neurological symptoms, today announced that it will present at the 2026 BIO International Convention taking place in San Diego, USA, from June 22-25. The company’s presentation is scheduled for Monday, June 22 at 4:30 PM in Theater 4. The presentation will highlight Azafaros’ progress in developing nizubaglustat, its lead investigational compound for the treatment of rare lysosomal storage disorders with neurological involvement, including GM1 and GM2 gangliosidoses (GM1/GM2) and Niemann-Pick type C disease (NPC). Nizubaglustat is currently in two Phase 3 registrational studies (NAVIGATE) treating patients with GM1/GM2 and NPC and expects to report topline data from the studies in 2028. “BIO provides an important opportunity to update our progress as we continue advancing nizubaglustat through late-stage clinical development,” said Stefano Portolano, CEO at A
Teledyne FLIR Defense Launches Black Recon™ Autonomous Micro-Drone15.6.2026 07:05:00 EEST | Press release
Teledyne FLIR Defense, part of Teledyne Technologies Incorporated (NYSE: TDY), today announced at Eurosatory the market launch of Black Recon™, an autonomously launched micro-drone system that delivers continuous, untethered reconnaissance from military vehicles and fixed installations. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260614388428/en/ Teledyne FLIR Defense announced at Eurosatory the market launch of Black Recon™, an autonomously launched micro-drone that delivers continuous, untethered reconnaissance from military vehicles and fixed installations. Black Recon allows crews to launch, operate, recover, and recharge up to three UAS without leaving their platform, reducing operator risk. Designed for vehicle integration, Black Recon allows crews to launch, operate, recover, and recharge up to three unmanned aerial systems without leaving their platform, reducing risk and accelerating decision-making. “Black Recon
OM Pharma to Unveil the Largest Multi-Country Real-World Evidence Study on Broncho‑Vaxom® (OM‑85) for RTI Prevention at EAACI 202614.6.2026 11:00:00 EEST | Press release
OM Pharma will reveal preliminary results from the REACH study at the European Academy of Allergy and Clinical Immunology (EAACI) Congress. REACH is the first and largest multi-country real-world evidence (RWE) study to date evaluating the impact of Broncho-Vaxom® in patients with recurrent respiratory tract infections (RTIs).1,2 The findings offer critical new clinical evidence of the therapy's effectiveness in everyday clinical practice. In a real-world cohort of 15,794 paediatric (aged >1 year), adolescent, adult and elderly patients in China, Italy, and Belgium, Broncho-Vaxom® was associated with reductions in RTI recurrence and healthcare utilisation at 12 and 24 months after treatment initiation, compared with the 12 months prior to starting the therapy.1 “The REACH real-world evidence study shows that Broncho-Vaxom® can significantly reduce infections requiring medical visits across age groups and co-morbidities,” said Anna Thomas, Chief Scientific Officer at OM Pharma. “Recurre
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom